Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Cancer Cachexia Overview 9 Therapeutics Development 10 Pipeline Products for Cancer Cachexia - Overview 10 Pipeline Products for Cancer Cachexia - Comparative Analysis 11 Cancer Cachexia - Therapeutics under Development by Companies 12 Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes 14 Cancer Cachexia - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Cancer Cachexia - Products under Development by Companies 18 Cancer Cachexia - Products under Investigation by Universities/Institutes 20 Cancer Cachexia - Companies Involved in Therapeutics Development 21 Acacia Pharma Limited 21 Aeterna Zentaris Inc. 22 Aphios Corporation 23 Atara Biotherapeutics, Inc. 24 Eli Lilly and Company 25 Helsinn Healthcare S.A. 26 Incyte Corporation 27 Novartis AG 28 Obexia AG 29 PsiOxus Therapeutics Limited 30 RaQualia Pharma Inc. 31 Viking Therapeutics, Inc. 32 Cancer Cachexia - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Combination Products 34 Assessment by Target 35 Assessment by Mechanism of Action 37 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Drug Profiles 43 (formoterol fumarate + megestrol acetate) - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 anamorelin hydrochloride - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 ATA-842 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 AUSRM-057 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 bimagrumab - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 C-1889 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 DLN-101 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 dronabinol - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 espindolol - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 EXT-400 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Foxo1-nRNA - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 HM-03 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 landogrozumab - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 macimorelin acetate - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia and Cancer Cachexia - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 NBD Peptide - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 OBX-1201 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 RQ-00433412 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 ruxolitinib phosphate - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Small Molecule to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Synthetic Peptides for Cancer Cachexia - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 tertomotide - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 VK-5211 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Cancer Cachexia - Recent Pipeline Updates 82 Cancer Cachexia - Dormant Projects 101 Cancer Cachexia - Discontinued Products 103 Cancer Cachexia - Product Development Milestones 104 Featured News & Press Releases 104 Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology 104 Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102 105 Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130 105 Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130 106 Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 107 Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study 108 Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia 108 Mar 17, 2011: PsiOxus Therapeutics Initiates Phase II Clinical Study Of Wasting Disease Therapeutic MT-102 109 Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics 110 Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June 111 Appendix 112 Methodology 112 Coverage 112 Secondary Research 112 Primary Research 112 Expert Panel Validation 112 Contact Us 112 Disclaimer 113

List of Tables Number of Products under Development for Cancer Cachexia, H1 2016 10 Number of Products under Development for Cancer Cachexia - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H1 2016 20 Cancer Cachexia - Pipeline by Acacia Pharma Limited, H1 2016 21 Cancer Cachexia - Pipeline by Aeterna Zentaris Inc., H1 2016 22 Cancer Cachexia - Pipeline by Aphios Corporation, H1 2016 23 Cancer Cachexia - Pipeline by Atara Biotherapeutics, Inc., H1 2016 24 Cancer Cachexia - Pipeline by Eli Lilly and Company, H1 2016 25 Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H1 2016 26 Cancer Cachexia - Pipeline by Incyte Corporation, H1 2016 27 Cancer Cachexia - Pipeline by Novartis AG, H1 2016 28 Cancer Cachexia - Pipeline by Obexia AG, H1 2016 29 Cancer Cachexia - Pipeline by PsiOxus Therapeutics Limited, H1 2016 30 Cancer Cachexia - Pipeline by RaQualia Pharma Inc., H1 2016 31 Cancer Cachexia - Pipeline by Viking Therapeutics, Inc., H1 2016 32 Assessment by Monotherapy Products, H1 2016 33 Assessment by Combination Products, H1 2016 34 Number of Products by Stage and Target, H1 2016 36 Number of Products by Stage and Mechanism of Action, H1 2016 38 Number of Products by Stage and Route of Administration, H1 2016 40 Number of Products by Stage and Molecule Type, H1 2016 42 Cancer Cachexia Therapeutics - Recent Pipeline Updates, H1 2016 82 Cancer Cachexia - Dormant Projects, H1 2016 101 Cancer Cachexia - Dormant Projects (Contd..1), H1 2016 102 Cancer Cachexia - Discontinued Products, H1 2016 103 List of Figures Number of Products under Development for Cancer Cachexia, H1 2016 10 Number of Products under Development for Cancer Cachexia - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Products, H1 2016 17 Assessment by Monotherapy Products, H1 2016 33 Number of Products by Top 10 Targets, H1 2016 35 Number of Products by Stage and Top 10 Targets, H1 2016 35 Number of Products by Top 10 Mechanism of Actions, H1 2016 37 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 37 Number of Products by Routes of Administration, H1 2016 39 Number of Products by Stage and Routes of Administration, H1 2016 39 Number of Products by Molecule Types, H1 2016 41 Number of Products by Stage and Molecule Types, H1 2016 41

Acacia Pharma Limited Aeterna Zentaris Inc. Aphios Corporation Atara Biotherapeutics, Inc. Eli Lilly and Company Helsinn Healthcare S.A. Incyte Corporation Novartis AG Obexia AG PsiOxus Therapeutics Limited RaQualia Pharma Inc. Viking Therapeutics, Inc.